E. coli-derived recombinant human IL-37/IL-1F7 Lys27-Asp192 Accession # NP_775297
Detects human IL-37/IL-1F7 in direct ELISAs. In direct ELISAs, no cross‑reactivity with recombinant human (rh) IL-1 alpha, rhIL-1 beta, rhIL-1ra, rhIL-36Ra/IL-1F5, rhIL-36 alpha/IL-1F6, rhIL-36 beta/IL-1F8, or rhIL-18/IL-1F4 is observed.
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for IL-37/IL-1F7 Antibody (261506) [Unconjugated]
IL1H4IL1F7 (canonical product IL-1F7b)
IL-1H4IL-1F7b (IL-1H4, IL-1H, IL-1RP1)
IL1RP1interleukin 1 family member 7
interleukin 1 family, member 7 (zeta)
interleukin 1, zeta
interleukin-1 family member 7
Interleukin-1 homolog 4
interleukin-1 superfamily z
Human interleukin 1 family member 7 (IL-1F7), also named FIL-1Z, IL-1H4, and IL-1RP1, belongs to the IL-1 cytokine family, which currently has ten members. With the exception of IL-18 that maps to human chromosome 11, all other IL-1 family members map to the same cluster on human chromosome 2. Five alternatively spliced transcripts that arise through alternate exon usage have been described. These transcripts encode five different IL-1F7 isoforms (IL-1F7a through e also referred to as isofoms 1 through 5) that have distinct expression profiles. Polymorphism in the protein sequence of IL-1F7 isoforms also exists. Like IL-1 alpha, IL-1 beta and IL-18, all of the IL-1F7 variants lack a typical signal peptide. The longest IL-1F7 transcript, referred to as IL-1F7b or IL-1F7 isoform 1, encodes a 218 amino acid (aa) residues proprotein containing a 45 aa propeptide, which is removed by caspase-1 to generate the 173 aa mature segment. Mature IL-1F7b and other IL-1F7 variants lack potential N-linked glycosylation sites. The secreted mature IL-17F7b was reported to exist as a nondisulfide linked homodimers in solution, IL-1F7 shares approximately 21%, 24%, and 30% aa sequence identity with mature IL-1 alpha, IL-1 beta and IL-1ra, respectively. Mouse IL-1F7 has not been reported, but human IL-1F7 is active on mouse cells. IL-1F7b binds to IL-18 R alpha with low affinity but does not exert any IL-18 agonistic or antagonistic effects. IL-1F7b also binds to the IL-18BP to enhance the antagonistic effects of IL-18BP. It has been proposed that IL-1F7b form a trimeric complex with IL-18BP and IL-18 R beta. This complex blocks IL-18 activity by sequestering the signal transducing subunit and preventing it from participating in IL-18 signaling (1‑8).
Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
Kumar S. et al. (2000) J. Biol. Chem. 275:10308.
Busfield S.J. et al. (2000) Genomics 66:213.
Kumar S. et al. (2002) Cytokine 18:61.
Bufler, P. et al. (2002) Proc. Natl. Acad. Sci. USA 99:13723.
Gao, W. et al. (2003) J. Immunol. 170:1077.
Pan, G. et al. (2001) Cytokine 13:1.
Sims, J.E. et al. (2001) Trends Immunol. 22:533.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our IL-37/IL-1F7 Antibody (261506) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.